A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058)

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

Study Overview

• Status: Not yet recruiting
• Conditions: Neurofibromatosis 1; JMML; Leukemia, Juvenile Myelomonocytic; JCML; CBL Syndrome
• Intervention / Treatment: Drug: Trametinib; Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine

Detailed Description

Primary Objectives:

1. To determine the safety of combining trametinib with azacitidine for patients with newly diagnosed lower-risk JMML.
2. To determine the safety of combining trametinib with azacitidine (Aza), fludarabine (FLA) and cytarabine for patients with newly diagnosed high-risk JMML.

Dosing:

Patients with newly diagnosed lower-risk JMML will be treated with daily azacitidine for 5 days in combination with daily trametinib for 28 days per course for up to 12 courses. Patients with newly diagnosed high-risk JMML will be treated with daily azacitidine, fludarabine, and cytarabine for 5 days in combination with daily trametinib for 28 days per course for up to 2 courses.

• Study Type: Interventional
• Enrollment (Estimated): 58
• Phase: Phase 2; Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Age - Patients must be ≥ 1 month and ≤21 years of age at enrollment.

Diagnosis

- Patients must meet the World Health Organization criteria for JMML. The diagnosis is made based on the following criteria.

Category 1 (all of the following):*

• Splenomegaly (physical examination or imaging are acceptable)
• > 1000 (1x10^9/μL) circulating monocytes
• < 20% Blasts in the bone marrow or peripheral blood
• Absence of the t(9;22) or BCR/ABL fusion gene *The diagnostic criteria must include all features in category 1 and EITHER (i) one of the features in Category 2 OR (ii) two features from Category 3 to make the diagnosis.

JMML Category 2 (at least one of the following if at least two Category 3 criteria are not present):

• Somatic mutation in RAS (NRAS, KRAS, RRAS or RRAS2) or PTPN11
• Clinical diagnosis of NF1 or NF1 gene mutation
• Somatic alteration in CBL (inclusive of patients with CBL syndrome)
• Monosomy 7

JMML Category 3 (at least two of the following if no Category 2 criteria are met):

• Circulating myeloid precursors
• White blood cell count, >10 000 (10x109/ μL)
• Increased Hemoglobin F for age
• Clonal cytogenetic abnormality

Performance Level

• Karnofsky > 50% for patients ≥ 16 years of age
• Lansky > 50% for patients < 16 years of age.

Prior Therapy

• No prior leukemia directed therapy is permitted with the exception of:

  1. Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of trametinib.
  2. Cytoreduction with 6-mercaptopurine (6-MP) 6-MP can be initiated and continued for up to 72 hours prior to the start of trametinib.

  3. Intrathecal (IT) cytarabine, IT methotrexate or triple IT therapy (cytarabine, methotrexate and hydrocortisone) within 7 days of enrollment as part of a diagnostic evaluation.

     No prior hematopoietic stem cell transplant is permitted.

     Adequate Renal Function Defined as:

• Patient must have a calculated creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73m2 OR a normal serum creatinine based on age/gender in the chart below:

Maximum Serum Creatinine (mg/dL):

• 1 month to < 6 months old - Male: 0.4, Female 0.4
• 6 months to <1 year old - Male 0.5, Female 0.5
• 1 to < 2 years old - Male: 0.6, Female: 0.6
• 2 to < 6 years old - Male:0.8, Female: 0.8
• 6 to < 10 years old - Male: 1, Female: 1
• 10 to < 13 years old - Male: 1.2, Female: 1.2
• 13 to < 16 years old - Male: 1.5, Female: 1.4
• ≥ 16 years old - Male: 1.7, Female: 1.4 The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.

Adequate Liver Function Defined as:

• Direct bilirubin < 1.5 x upper limit of normal (ULN) for age or normal, AND alanine transaminase (ALT) < 5 x ULN for age.
• The hepatic requirements are waived for patients with known or suspected liver involvement by leukemia and will not be evaluable for hepatotoxicity. This must be reviewed and approved by the study chair or vice chair.

Adequate Cardiac Function Defined as:

• Ejection fraction of > or = to 50% by echocardiogram, OR
• Ejection fraction of > or = to 50% by radionuclide angiogram (MUGA).

Reproductive Function

A. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.

B. Female patients with infants must agree not to breastfeed their infants while on this study.

C. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatment.

Exclusion Criteria:

• Patients cannot have a known allergy to any of the drugs used in the study.
• Patients cannot have a systemic fungal, bacterial, viral, or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The patient needs to be off pressors and have negative blood cultures for 48 hours.
• Patients cannot have a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
• Patients cannot have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results.
• Patients cannot have a clinical or molecular diagnosis of Noonan syndrome. Note: patients with either neurofibromatosis type 1 or Casitas B-lineage lymphoma (CBL) syndrome (also known as Noonan-like syndrome), are eligible to enroll. Patients with Down syndrome are excluded from the study.
• Patient cannot have had prior use of hematopoietic growth factors, biologics (anti-neoplastic agent), or XRT.
• Patients cannot be taking any medications for treatment of left ventricular systolic dysfunction.
• Patients cannot have a history of or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
• Patients cannot have had prior use of any MEK inhibitor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lower-risk patients; Lower-risk patients are defined as having a mutational burden of one clonal alteration AND a low DNA methylation classification.	Drug: Trametinib; PO or NG QD Days 1-28 For patients age < 6 years: 0.032 mg/kg/day at max dose = 2mg/day For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day; Other Names: TMT212-NXA; GSK1120212B; Drug: Azacitidine; IV over 30 minutes Days 1-5 Age < 1 year or weight <10kg: 2.5 mg/kg/day Age ≥ 1 year and weight ≥ 10kg: 75 mg/m2/day; Other Names: Vidaza; 5-azacytidine
Experimental: High-risk patients; High-risk patients are defined as having as having a mutational burden of more than one clonal alteration AND/OR an intermediate or high DNA methylation classification.	Drug: Trametinib; PO or NG QD Days 1-28 For patients age < 6 years: 0.032 mg/kg/day at max dose = 2mg/day For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day; Other Names: TMT212-NXA; GSK1120212B; Drug: Azacitidine; IV over 30 minutes Days 1-5 Age < 1 year or weight <10kg: 2.5 mg/kg/day Age ≥ 1 year and weight ≥ 10kg: 75 mg/m2/day; Other Names: Vidaza; 5-azacytidine; Drug: Fludarabine; IV over 30 minutes Days 6-10 30 mg/m2/day (1mg/kg if <12 kg); Other Names: FLUDARA FOR INJECTION; Drug: Cytarabine; IV over 3 hours Days 6-10 2000 mg/m2/day (67mg/kg if <12 kg); Other Names: Ara-C; Cytosar; Cytosine arabinoside

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine the safety of combining trametinib with azacitidine for patients with newly diagnosed lower-risk JMML.	The incidence of dose limiting toxicities (DLTs) after the 1st course of therapy will be measured at different dose levels.	At the end of the evaluation period of Cycle 1 (defined as 28 day cycle of therapy plus 30 days following the last dose of study therapy)
To determine the safety of combining trametinib with azacitidine (Aza), fludarabine (FLA) and cytarabine for patients with newly diagnosed high-risk JMML.	The incidence of dose limiting toxicities (DLTs) after the 1st course of therapy will be measured at different dose levels.	At the end of the evaluation period of Cycle 1 (defined as 28 day cycle of therapy plus 30 days following the last dose of study therapy)

Collaborators and Investigators

• Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Study record dates

Study Major Dates

• Study Start (Estimated): November 30, 2023
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2029

Study Registration Dates

• First Submitted: April 25, 2023
• First Submitted That Met QC Criteria: May 4, 2023
• First Posted (Actual): May 9, 2023

Study Record Updates

• Last Update Posted (Actual): October 31, 2023
• Last Update Submitted That Met QC Criteria: October 27, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms; Bone Marrow Diseases; Hematologic Diseases; Genetic Diseases, Inborn; Neuromuscular Diseases; Neurodegenerative Diseases; Neoplasms, Nerve Tissue; Peripheral Nervous System Diseases; Heredodegenerative Disorders, Nervous System; Neoplastic Syndromes, Hereditary; Myelodysplastic-Myeloproliferative Diseases; Nerve Sheath Neoplasms; Neurocutaneous Syndromes; Leukemia, Myeloid; Neurofibroma; Leukemia; Leukemia, Myelomonocytic, Juvenile; Neurofibromatoses; Neurofibromatosis 1; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Protein Kinase Inhibitors; Azacitidine; Fludarabine; Cytarabine; Trametinib
• Other Study ID Numbers: T2020-004

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No